Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolterodine SCHEMBL29635996 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL3064 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL580446 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL29379290 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL820421 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1260827 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL4840247 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL9221238 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL617185 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1262758 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2622 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024015331-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR MULTIPLE SCLEROSIS | GENENTECH, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-11759420-B2 | Inhalable particles | CRYSTEC LTD (GB) | 2023-09-19 | — | — | US | claimed |
| US-20220331243-A1 | INHALABLE PARTICLES | CRYSTEC LTD (GB) | 2022-10-20 | — | — | US | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-11351115-B2 | Inhalable particles | CRYSTEC LTD (GB) | 2022-06-07 | — | — | US | claimed |
| WO-2020231948-A1 | DIAGNOSIS OF MULTIPLE SCLEROSIS IN HUMAN AND ANIMAL SUBJECTS | OP-T LLC (US) | 2020-11-19 | — | — | WO | claimed |
| US-20200230053-A1 | Inhalable Particles | CRYSTEC LTD (GB) | 2020-07-23 | — | — | US | claimed |
| US-20030095926-A1 | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract | NOVADEL PHARMA INC. | 2003-05-22 | — | — | US | claimed |
| WO-2003039519-A2 | DUAL CONTROLLED RELEASE DOSAGE FORM | OSMOTICA CORP. (VG) | 2003-05-15 | — | — | WO | claimed |
| WO-2003039436-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING OXYBUTYNIN | OSMOTICA COSTA RICA SOCIEDAD ANONIMA (CR) | 2003-05-15 | — | — | WO | claimed |
| WO-2003039464-A2 | ANTIMUSCARINIC AEROSOL | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2003026564-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF URINARY DISORDERS | PHARMACIA AB (SE) | 2003-04-03 | — | — | WO | claimed |
| US-20030060513-A1 | Pharmaceutical composition | PHARMACIA AB (SE) | 2003-03-27 | — | — | US | claimed |
| US-6310103-B1 | ADMINISTERING TO A MAMMAL SUFFERING FROM URINARY INCONTINENCE INCONTINENCE WHILE REDUCING ADVERSE EFFECT ASSOCITED WITH RACEMIC OR R-ENANTIIOMER OF TOLTERODINE, A S(-)-2-(ALPHA-(2-(DIISOPROPYLAMINO)ETHYL)BENZYL)-P-CRESOL | BRIDGE PHARMA, INC. | 2001-10-30 | — | — | US | claimed |
| EP-0924983-A4 | S(-)-TOLTERODINE IN THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | ABERG GUNNAR (US) | 1999-08-25 | — | — | EP | claimed |
| EP-0924983-A1 | S(-)-TOLTERODINE IN THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | Aberg, Gunnar (US) | 1999-06-30 | — | — | EP | claimed |
| WO-1998003067-A1 | S(-)-TOLTERODINE IN THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | ABERG GUNNAR (US) | 1998-01-29 | — | — | WO | claimed |